DOCSLIB.ORG

A New Paradigm in Cell Signaling and Cancer Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A New Paradigm in Cell Signaling and Cancer Therapy Oncogene (2010) 29, 1865–1882 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc REVIEW Dependence receptors: a new paradigm in cell signaling and cancer therapy D Goldschneider and P Mehlen Apoptosis, Cancer and Development Laboratory- Equipe labellise´e ‘La Ligue’, CNRS UMR5238, Centre Le´on Be´rard, Universite´ de Lyon, Lyon, France Dependence receptors (DRs) now form a family of more (Stupack et al., 2001). All of them are involved in both than a dozen membrane receptors that are not linked by nervous system development and cancer progression. their structure, but by common functional traits. The most notable is their ability to trigger two opposite signaling pathways: in the presence of ligand, these receptors Dependence receptors: a short history activate classic signaling pathways implicated in cell survival, migration and differentiation. In the absence of Neurotrophin receptor p75NTR was the first DR to be ligand, they do not stay inactive, rather they elicit an described. P75NTR was discovered as one of two apoptotic signal. Thus, cells expressing this kind of receptors able to bind nerve growth factor (Chao receptor are dependent on the presence of ligand in the et al., 1986), the other being TrkA (Kaplan et al., extracellular environment to survive. This review will 1991). TrkA was rapidly shown to mediate the known recapitulate the increasing data regarding the molecular responses to NGF, such as neurite outgrowth and mechanisms associated with DRs, their potential implica- neuronal survival (Lee et al., 2001a; Lykissas et al., tion during development, as well as their deregulation 2007), whereas the precise biological role of p75NTR during tumorigenesis and, finally, their emergence as new remained misunderstood. p75NTR was shown to collabo- possible therapeutic targets for cancer treatment. rate with TrkA to form high-affinity sites for NGF Oncogene (2010) 29, 1865–1882; doi:10.1038/onc.2010.13; binding (Hempstead et al., 1991). In addition, p75NTR published online 22 February 2010 was shown to alter the ligand specificity of other Trk receptors. For example, brain-derived neurotrophic Keywords: dependence receptors; apoptosis; caspase; factor, NT3 and NT4/5 can all bind TrkB in the absence tumor progression; cancer therapy of p75NTR, whereas only brain-derived neurotrophic factor does so in the presence of p75NTR. In contrast, coexpression of p75NTR with TrkC results in a relaxation Membrane receptors are classically considered as inactive in its absolute specificity for NT3 (Hempstead, 2002). At unless bound to their ligand. However, increasing observa- the time of its discovery, p75NTR was considered as a tions demonstrate that some receptors, in addition to their unique type of protein but, subsequently, a large ‘positive’ signaling when their ligand is present, transduce a superfamily of tumor necrosis factor (TNF) receptors ‘negative’ signal that induces apoptosis in the absence of were found to share the overall structure of p75NTR ligand (Figure 1). Cells expressing these receptors are thus (Liepinsh et al., 1997). Identification of this superfamily dependent on the presence of ligand to survive. These helped elucidate some of the biological functions of receptors are named ‘dependence receptors.’ To date, the p75NTR, including its link to cell death regulation. The dependence receptor (DR) family is composed of more relationship between these TNF death receptors, which than a dozen members including DCC (deleted in color- induce cell death on binding of proapoptotic ligand such ectal carcinoma) (Mehlen et al., 1998), UNC5Hs (un- as TNF or FasL, and p75NTR, which binds NGF, a coordinated 5 homologs), neogenin (Matsunaga et al., trophic factor known to induce cell survival, led DE NTR 2004), p75 (p75 neurotrophin receptor) (Rabizadeh Bredesen and colleagues to propose that p75NTR induces et al., 1993), RET (rearranged during transfection) cell death when unoccupied by NGF, whereas binding (Bordeaux et al., 2000), TrkC (tyrosine kinase receptor C) of NGF blocks apoptosis (Rabizadeh et al., 1993) (Tauszig-Delamasure et al., 2007), Ptc (patched) (Thibert (Figure 2 and Table 1). This finding suggested that et al., 2003), EphA4 (ephrin type A receptor 4) (Furne p75NTR expression creates a state of cellular dependence et al., 2009), ALK (anaplastic lymphoma kinase) (Mourali on NGF. Further studies with knockout mice confirmed et al.,2006),MET(Tulasneet al., 2004) and some integrins this notion. First, p75NTR-deficient mice have an increased number of cholinergic neurons, somal hyper- Correspondence: Dr P Mehlen, Apoptosis, Cancer and Development trophy and hyperinnervation in some areas of the Laboratory- Equipe labellise´e ‘La Ligue’, CNRS UMR5238, Centre hippocampus (Yeo et al., 1997; Naumann et al., 2002). Le´on Be´rard, Universite´de Lyon, 28 rue Laennec, Lyon, Rhone 69008, In addition, crossing NGF hemizygous mice, which France. E-mail: [email protected] display a reduction in cholinergic cell numbers, with NTR NTR Received 1 October 2009; revised 2 January 2010; accepted 6 January p75 null mice showed that loss of p75 partially 2010; published online 22 February 2010 restores cholinergic cell numbers (Naumann et al., A new paradigm in cell signaling and cancer therapy D Goldschneider and P Mehlen 1866 2002). However, the overall picture of p75NTR function binding rather than ligand withdrawal (Casaccia-Bon- became more complicated when some studies showed nefil et al., 1996; Frade et al., 1996). Particularly, in that p75NTR induced apoptosis in response to ligand addition to its ability to bind mature neurotrophins, Table 1 DRs and their known ligands Receptors Ligands p75NTR NGF, proNGF, BDNF, NT-3, NT-4/5, b-amyloid, prion DCC netrin-1, netrin-4 Neogenin netrin-1, RGMa, RGMb, RGMc, netrin-3, netrin-4 Unc50s netrin-1, netrin-4 RET GDNF, neurturin, artemin, persephin Ptc Shh TrkC NT-3 EphA4 ephrinB3, ephrinA1, ephrinA4 ALK pleiotrophin, midkin, jeb Survival, MET HGF Migration, APOPTOSIS AR androgens Differentiation Integrin avb3 extracellular matrix and a5b1 Figure 1 The DR model. DRs have two faces: in the presence of their respective ligand, they transduce a positive signal of The above listed are the DRs and their known ligands. In case of differentiation, migration or survival, whereas in the absence of multiple ligands, those which were shown to block apoptotic function their ligand, they do not stay inactive but, rather, induce apoptosis. are underlined. ALK is a particular case: its putative ligands have not Thus, cells expressing such receptors are dependent on ligand yet been tested for blocking apoptosis, only agonist antibodies have availability for survival. been used. Figure 2 Representation of the DR family. The functional domains present in extra and intracellular domains are represented. DRs are not related to each other according to their structure, but according to their ability to induce apoptosis in the absence of ligand. All of them are caspase substrates, except p75NTR and integrins. The position of caspase cleavage sites is indicated. Localization of ADD, which has been more or less precisely determined depending on receptor, is indicated by double arrows. Oncogene A new paradigm in cell signaling and cancer therapy D Goldschneider and P Mehlen 1867 other cell-death-inducing ligands have been proposed embryogenesis. In vertebrates, besides netrin-1, four for p75NTR, such as pro-NGF (Lee et al., 2001b), other netrins have been described: netrin-2/3/2like, b-amyloid (Yaar et al., 2002) and prion (Della-Bianca netrin-4/b, netrin-G1 and netrin-G2 (Puschel, 1999; et al., 2001) peptides. The decision between ligand- Mehlen and Mazelin, 2003). Netrins are structurally induced apoptosis and ligand-inhibited apoptosis related to the short arm of laminin (g for netrin 1–3 and mediated by p75NTR likely depends on cell type and b for netrin-4, G1 and G2). Netrins 1–4 are secreted, development stage (Barrett and Bartlett, 1994). Because whereas netrin-G1 and G2 are membrane anchored by the idea of a receptor triggering apoptosis when means of a glycophosphatidylinol tail. Secreted netrins unbound to its ligand contradicted the dogma regarding exert their biological functions by binding to receptors receptor signaling and the trophic theory, considering such as DCC, UNC5, neogenin and DSCAM, whereas p75NTR as a classic death receptor had more success than netrin Gs do not interact with these receptors (Rajase- considering it as a DR. Consequently, DR p75NTR has kharan and Kennedy, 2009). Interestingly, netrin-5 has been rather forgotten, although it was the first to be recently appeared in databases, which seems to be described and no definitive evidence has demonstrated related to the netrin 1–3 group according to its sequence. that it is not a DR. Netrin-1 is the most studied member of the netrin family The concept reemerged with DCC. DCC was dis- and to date it seems to be the main ligand for DCC, as covered in 1990 as a putative cell-surface receptor well as for UNC5 receptors (see below), although a encoded by a gene frequently deleted through allelic recent report mentioned that netrin-4 could interact with loss in colorectal carcinoma (Fearon et al., 1990). DCC and UNC5H1 (Qin et al., 2007). Observation that DCC expression is reduced or lost in The UNC5 receptor was initially identified in colorectal cancer led to the proposal that DCC Caenorhabditis elegans as an axonal guidance trans- expression represented a constraint for disease progres- membrane receptor (Leung-Hagesteijn et al., 1992) and, sion and is therefore a tumor suppressor. This hypo- on the basis of a genetic screen, was predicted to interact thesis was supported by the fact that DCC expression is with UNC6 (the C. elegans netrin-1 ortholog) (Hedge- lost or reduced in various cancers (Mehlen and Fearon, cock et al., 1990). Four homologs of UNC5 have been 2004) and that its loss of expression is associated with described in mammals (UNC5H1, 2, 3 and 4 in rodents poor prognosis (Shibata et al., 1996; Sun et al., 1999).
Load more

Recommended publications
  • Patents Related to EPH Receptors and Ligands
    NEWS & ANALYSIS discuss EPH receptor–ephrin signalling Patents related to EPH receptors and its role in disorders such as tumour and ligands growth and progression, nerve injury and inflammation, and highlight therapeutic EPH receptors are a family of receptor approaches that are currently under tyrosine kinases that, together with their investigation. Here in TABLE 1 we highlight ligands, are involved in cell positioning, patent applications published in the past tissue and organ patterning as well as the 3 years related to EPH receptors and ligands. control of cell survival. In their Review Data were researched using the Espacenet on page 39, Lackman and colleagues database. Table 1 | Recent patent applications related to EPH receptors and ligands Nature Reviews | Drug Discovery Publication Applicants Subject numbers NZ 581397 AstraZeneca Pyrimidine compounds that inhibit EPH receptors and are useful for treating cancer HK 1108702 Sanford-Burnham Peptides that selectively bind to EPH type-B receptors (EPHBs); useful for tumour imaging and the Institute treatment of neoplastic disease, neurological disease and vascular disease US 2013091591 California Institute of During angiogenesis, arterial cells express ephrin B2, and its receptor EPHB4 is expressed on venous Technology cells; this distinction can be used in methods to alter angiogenesis and to assess the effect of drugs WO 2013052710 Expression Pathology Selected reaction monitoring mass spectrometry-based and multiple reaction monitoring mass spectrometry-based assays for quantifying
    [Show full text]
  • A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
    414 Original Article A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma David A. Reardon, MDa,b; Scott Turner, MDc; Katherine B. Peters, MD, PhDc; Annick Desjardins, MDc; Sridharan Gururangan, MDa,b; John H. Sampson, MD, PhDa; Roger E. McLendon, MDd; James E. Herndon II, PhDe; Lee W. Jones, PhDf; John P. Kirkpatrick, MD, PhDf; Allan H. Friedman, MDa; James J. Vredenburgh, MDc; Darell D. Bigner, MD, PhDd; and Henry S. Friedman, MDa,b; Durham, North Carolina Key Words ability effect of VEGF inhibitors, the Radiologic Assessment in Neu- Glioblastoma, angiogenesis, vascular endothelial growth factor, ro-Oncology (RANO) criteria were recently implemented to bet- malignant glioma ter assess response among patients with glioblastoma. Although bevacizumab improves survival and quality of life, eventual tumor progression is the norm. Better understanding of resistance mech- Abstract anisms to VEGF inhibitors and identification of effective therapy Glioblastoma, the most common primary malignant brain tumor after bevacizumab progression are currently a critical need for pa- among adults, is a highly angiogenic and deadly tumor. Angiogen- tients with glioblastoma. (JNCCN 2011;9:414–427) esis in glioblastoma, driven by hypoxia-dependent and indepen- dent mechanisms, is primarily mediated by vascular endothelial growth factor (VEGF), and generates blood vessels with distinctive features. The outcome for patients with recurrent glioblastoma is poor because of ineffective therapies. However, recent encourag- ing rates of radiographic response and progression-free survival, Malignant gliomas, including the most common sub- and adequate safety, led the FDA to grant accelerated approval of type of glioblastoma, are rapidly growing destructive tu- bevacizumab, a humanized monoclonal antibody against VEGF, for mors that extensively invade locally but rarely metasta- the treatment of recurrent glioblastoma in May 2009.
    [Show full text]
  • Neurotrophin-3 Production Promotes Human Neuroblastoma Cell Survival by Inhibiting Trkc-Induced Apoptosis
    Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis Jimena Bouzas-Rodriguez, … , Servane Tauszig-Delamasure, Patrick Mehlen J Clin Invest. 2010;120(3):850-858. https://doi.org/10.1172/JCI41013. Research Article Oncology Tropomyosin-related kinase receptor C (TrkC) is a neurotrophin receptor with tyrosine kinase activity that was expected to be oncogenic. However, it has several characteristics of a tumor suppressor: its expression in tumors has often been associated with good prognosis; and it was recently demonstrated to be a dependence receptor, transducing different positive signals in the presence of ligand but inducing apoptosis in the absence of ligand. Here we show that the TrkC ligand neurotrophin-3 (NT-3) is upregulated in a large fraction of aggressive human neuroblastomas (NBs) and that it blocks TrkC-induced apoptosis of human NB cell lines, consistent with the idea that TrkC is a dependence receptor. Functionally, both siRNA knockdown of NT-3 expression and incubation with a TrkC-specific blocking antibody triggered apoptosis in human NB cell lines. Importantly, disruption of the NT-3 autocrine loop in malignant human neuroblasts triggered in vitro NB cell death and inhibited tumor growth and metastasis in both a chick and a mouse xenograft model. Thus, we believe that our data suggest that NT-3/TrkC disruption is a putative alternative targeted therapeutic strategy for the treatment of NB. Find the latest version: https://jci.me/41013/pdf Research article Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis Jimena Bouzas-Rodriguez,1 Jorge Ruben Cabrera,1 Céline Delloye-Bourgeois,1 Gabriel Ichim,1 Jean-Guy Delcros,1 Marie-Anne Raquin,2 Raphaël Rousseau,3 Valérie Combaret,3 Jean Bénard,4 Servane Tauszig-Delamasure,1 and Patrick Mehlen1 1Apoptosis, Cancer and Development Laboratory–Equipe labellisée “La Ligue,” CNRS UMR5238, Université de Lyon, France.
    [Show full text]
  • A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
    cancers Article A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers Alexandre de Nonneville 1, Pascal Finetti 2 , José Adelaide 2, Éric Lambaudie 3, Patrice Viens 1, Anthony Gonçalves 1 , Daniel Birnbaum 2, Emilie Mamessier 2 and François Bertucci 1,2,* 1 Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CRCM, CNRS, INSERM, 13000 Marseille, France 2 Laboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Inserm UMR1068, CNRS UMR725, Aix-Marseille Université, 13000 Marseille, France 3 Department of Surgical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, CRCM, 13000 Marseille, France * Correspondence: [email protected]; Tel.: +33-4-91-22-35-37; Fax: +33-4-91-22-36-70 Received: 15 July 2019; Accepted: 9 August 2019; Published: 13 August 2019 Abstract: Triple negative breast cancer (TNBC) represent 15% of breast cancers. Histoclinical features and marketed prognostic gene expression signatures (GES) failed to identify good- and poor-prognosis patients. Tyrosine kinases (TK) represent potential prognostic and/or therapeutic targets for TNBC. We sought to define a prognostic TK GES in a large series of TNBC. mRNA expression and histoclinical data of 6379 early BCs were collected from 16 datasets. We searched for a TK-based GES associated with disease-free survival (DFS) and tested its robustness in an independent validation set. A total of 1226 samples were TNBC. In the learning set of samples (N = 825), we identified a 13-TK GES associated with DFS. This GES was associated with cell proliferation and immune response.
    [Show full text]
  • Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
    Author Manuscript Published OnlineFirst on March 29, 2019; DOI: 10.1158/1535-7163.MCT-18-0582 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Functional analysis of somatic mutations affecting receptor tyrosine kinase family in metastatic colorectal cancer Leslie Duplaquet1, Martin Figeac2, Frédéric Leprêtre2, Charline Frandemiche3,4, Céline Villenet2, Shéhérazade Sebda2, Nasrin Sarafan-Vasseur5, Mélanie Bénozène1, Audrey Vinchent1, Gautier Goormachtigh1, Laurence Wicquart6, Nathalie Rousseau3, Ludivine Beaussire5, Stéphanie Truant7, Pierre Michel8, Jean-Christophe Sabourin9, Françoise Galateau-Sallé10, Marie-Christine Copin1,6, Gérard Zalcman11, Yvan De Launoit1, Véronique Fafeur1 and David Tulasne1 1 Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T – Mechanisms of Tumorigenesis and Target Therapies, F-59000 Lille, France. 2 Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, F-59000 Lille, France 3 TCBN - Tumorothèque Caen Basse-Normandie, F-14000 Caen, France. 4 Réseau Régional de Cancérologie – OncoBasseNormandie – F14000 Caen – France. 5 Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, F-76000 Rouen, France. 6 Tumorothèque du C2RC de Lille, F-59037 Lille, France. 7 Department of Digestive Surgery and Transplantation, CHU Lille, Univ Lille, 2 Avenue Oscar Lambret, 59037, Lille Cedex, France. 8 Department of hepato-gastroenterology, Rouen University Hospital, Normandie Univ, UNIROUEN, Inserm U1245, IRON group, F-76000 Rouen, France. 9 Department of Pathology, Normandy University, INSERM 1245, Rouen University Hospital, F 76 000 Rouen, France. 10 Department of Pathology, MESOPATH-MESOBANK, Centre León Bérard, Lyon, France. 11 Thoracic Oncology Department, CIC1425/CLIP2 Paris-Nord, Hôpital Bichat-Claude Bernard, Paris, France.
    [Show full text]
  • Ephrinb3 Is an Anti-Apoptotic Ligand That Inhibits the Dependence Receptor Functions of Epha4 Receptors During Adult Neurogenesis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1793 (2009) 231–238 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamcr EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis Céline Furne a,1, Jerome Ricard b,1, Jorge Ruben Cabrera a, Laurent Pays a, John R. Bethea b, Patrick Mehlen a,⁎,2, Daniel J. Liebl b,⁎,2 a Laboratory Apoptosis Cancer and Development, CNRS UMR 5238, Center Léon Bérard, University of Lyon, Lyon, France b The Miami Project to Cure Paralysis and Department of Neurosurgery, University of Miami School of Medicine, Miami, FL, USA article info abstract Article history: Eph receptors have been implicated in regulating a diverse array of cellular functions in the developing Received 18 December 2007 nervous system. Recently, Eph receptors have been shown to promote cell death in adult germinal zones; Received in revised form 2 September 2008 however, their mechanisms of action remain ill-defined. In this study, we demonstrate that EphA4 is a new Accepted 15 September 2008 member of the dependence receptors family, which can initiate cell death in the absence of its ligand Available online 7 October 2008 ephrinB3. Upon removal of its ligand, EphA4 triggers cell death that is dependent on caspase activation as caspase inhibitors prevent cell death. EphA4 itself is cleaved by caspase-3-like caspase in the intracellular Keywords: Ephrin domain at position D773/774, which is necessary for cell death initiation as mutation of the cleavage site Eph receptor abolishes apoptosis.
    [Show full text]
  • Ephrin-A Binding and Epha Receptor Expression Delineate the Matrix Compartment of the Striatum
    The Journal of Neuroscience, June 15, 1999, 19(12):4962–4971 Ephrin-A Binding and EphA Receptor Expression Delineate the Matrix Compartment of the Striatum L. Scott Janis, Robert M. Cassidy, and Lawrence F. Kromer Department of Cell Biology and Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, DC 20007 The striatum integrates limbic and neocortical inputs to regulate matrix neurons. In situ hybridization for EphA RTKs reveals that sensorimotor and psychomotor behaviors. This function is de- the two different ligand binding patterns strictly match pendent on the segregation of striatal projection neurons into the mRNA expression patterns of EphA4 and EphA7. anatomical and functional components, such as the striosome Ligand–receptor binding assays indicate that ephrin-A1 and and matrix compartments. In the present study the association ephrin-A4 selectively bind EphA4 but not EphA7 in the lysates of ephrin-A cell surface ligands and EphA receptor tyrosine of striatal tissue. Conversely, ephrin-A2, ephrin-A3, and kinases (RTKs) with the organization of these compartments ephrin-A5 bind EphA7 but not EphA4. These observations im- was determined in postnatal rats. Ephrin-A1 and ephrin-A4 plicate selective interactions between ephrin-A molecules and selectively bind to EphA receptors on neurons restricted to the EphA RTKs as potential mechanisms for regulating the com- matrix compartment. Binding is absent from the striosomes, partmental organization of the striatum. which were identified by m-opioid
    [Show full text]
  • Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss
    Published OnlineFirst December 2, 2013; DOI: 10.1158/1535-7163.MCT-13-0817 Molecular Cancer Cancer Biology and Signal Transduction Therapeutics Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss Ellen M. Beauchamp1, Brittany A. Woods1,7, Austin M. Dulak1, Li Tan3, Chunxiao Xu1, Nathanael S. Gray2, Adam J. Bass1,6, Kwok-kin Wong1,4, Matthew Meyerson1,5,6, and Peter S. Hammerman1,6 Abstract The treatment of non–small cell lung cancer has evolved dramatically over the past decade with the adoption of widespread use of effective targeted therapies in patients with distinct molecular alterations. In lung squamous cell carcinoma (lung SqCC), recent studies have suggested that DDR2 mutations are a biomarker for therapeutic response to dasatinib and clinical trials are underway testing this hypothesis. Although targeted therapeutics are typically quite effective as initial therapy for patients with lung cancer, nearly all patients develop resistance with long-term exposure to targeted drugs. Here, we use DDR2-dependent lung cancer cell lines to model acquired resistance to dasatinib therapy. We perform targeted exome sequencing to identify two distinct mechanisms of acquired resistance: acquisition of the T654I gatekeeper mutation in DDR2 and loss of NF1. We show that NF1 loss activates a bypass pathway, which confers ERK dependency downstream of RAS activation. These results indicate that acquired resistance to dasatinib can occur via both second-site mutations in DDR2 and by activation of bypass pathways. These data may help to anticipate mechanisms of resistance that may be identified in upcoming clinical trials of anti-DDR2 therapy in lung cancer and suggest strategies to overcome resistance.
    [Show full text]
  • Global DNA Methylation Profiling Reveals Silencing of a Secreted Form
    Oncogene (2007) 26, 4243–4252 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc ORIGINAL ARTICLE Global DNA methylation profiling reveals silencing of a secreted form of Epha7in mouse and human germinal center B-cell lymphomas DW Dawson1, JS Hong1, RR Shen1, SW French1, JJ Troke1, Y-Z Wu2, S-S Chen2, D Gui1, M Regelson3, Y Marahrens3, HC Morse III4, J Said1, C Plass2 and MA Teitell1,5 1Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University, Columbus, OH, USA; 3Department of Human Genetics, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 4Laboratory of Immunopathology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD, USA and 5Molecular Biology Institute, Institute for Stem Cell Biology and Medicine, California NanoSystems Institute, Institute for Cell Mimetic Studies and Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA Most human lymphomas originate from transformed Introduction germinal center (GC) B lymphocytes. While activating mutations and translocations of MYC, BCL2 and BCL6 The TCL1 oncoprotein augments AKT activation and promote specific GC lymphoma subtypes, other genetic downstream signaling to promote cell proliferation and and epigenetic modifications that contribute to malignant survival (Teitell, 2005). Dysregulated expression of progression in the GC remain poorly defined. Recently, TCL1 is a frequent molecular alteration in non-Hodgkin aberrant expression of the TCL1 proto-oncogene was lymphomas (NHLs) that arise by transformation of identified in major GC lymphoma subtypes.
    [Show full text]
  • Open Full Page
    Published OnlineFirst March 29, 2012; DOI: 10.1158/0008-5472.CAN-11-3015 Cancer Integrated Systems and Technologies Research Phosphoproteomics Identifies Driver Tyrosine Kinases in Sarcoma Cell Lines and Tumors Yun Bai1, Jiannong Li1, Bin Fang5, Arthur Edwards1, Guolin Zhang1, Marilyn Bui2, Steven Eschrich4, Soner Altiok2, John Koomen3,5, and Eric B. Haura1 Abstract Driver tyrosine kinase mutations are rare in sarcomas, and patterns of tyrosine phosphorylation are poorly understood. To better understand the signaling pathways active in sarcoma, we examined global tyrosine phosphorylation in sarcoma cell lines and human tumor samples. Anti-phosphotyrosine antibodies were used to purify tyrosine phosphorylated peptides, which were then identified by liquid chromatography and tandem mass spectrometry. The findings were validated with RNA interference, rescue, and small-molecule tyrosine kinase inhibitors. We identified 1,936 unique tyrosine phosphorylated peptides, corresponding to 844 unique phos- photyrosine proteins. In sarcoma cells alone, peptides corresponding to 39 tyrosine kinases were found. Four of 10 cell lines showed dependence on tyrosine kinases for growth and/or survival, including platelet-derived growth factor receptor (PDGFR)a, MET, insulin receptor/insulin-like growth factor receptor signaling, and SRC family kinase signaling. Rhabdomyosarcoma samples showed overexpression of PDGFRa in 13% of examined cases, and sarcomas showed abundant tyrosine phosphorylation and expression of a number of tyrosine phosphorylated tyrosine kinases, including DDR2, EphB4, TYR2, AXL, SRC, LYN, and FAK. Together, our findings suggest that integrating global phosphoproteomics with functional analyses with kinase inhibitors can identify drivers of sarcoma growth and survival. Cancer Res; 72(10); 2501–11. Ó2012 AACR. Introduction subtypes. Furthermore, many sarcomas harbor balanced Sarcomas are rare and diverse malignancies that arise from translocations that result in unique fusion proteins that have mesenchymal derived connective tissues.
    [Show full text]
  • EPH/Ephrin Profile and EPHB2 Expression Predicts Patient Survival in Breast Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 16 EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer Anna-Maria Husa1,2, Željana Magić1, Malin Larsson3, Tommy Fornander4, Gizeh Pérez-Tenorio1 1Department of Clinical and Experimental Medicine, Division of Oncology, Linköping University, Linköping, Sweden 2Current address: CCRI, Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung e.V., Vienna, Austria 3Bioinformatics Infrastructure for Life Sciences (BILS) and Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden 4Department of Oncology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden Correspondence to: Gizeh Pérez-Tenorio, e-mail: [email protected] Keywords: EPHB2, EPH family, TaqMan array, gene expression, protein expression Received: July 03, 2015 Accepted: January 23, 2016 Published: February 8, 2016 ABSTRACT The EPH and ephrins function as both receptor and ligands and the output on their complex signaling is currently investigated in cancer. Previous work shows that some EPH family members have clinical value in breast cancer, suggesting that this family could be a source of novel clinical targets. Here we quantified the mRNA expression levels of EPH receptors and their ligands, ephrins, in 65 node positive breast cancer samples by RT-PCR with TaqMan® Micro Fluidics Cards Microarray. Upon hierarchical clustering of the mRNA expression levels, we identified a subgroup of patients with high expression, and poor clinical outcome. EPHA2, EPHA4, EFNB1, EFNB2, EPHB2 and EPHB6 were significantly correlated with the cluster groups and particularly EPHB2 was an independent prognostic factor in multivariate analysis and in four public databases. The EPHB2 protein expression was also analyzed by immunohistochemistry in paraffin embedded material (cohort 2).
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]